Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. You look at survival for patients with ...

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

MMRF continues to drive the critical global research collaborations that lead to scientific breakthroughs and improved patient outcomes ...

Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While people with multiple myeloma can live for ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, ...

DVRd therapy significantly improves MRD negativity and PFS, showing potential as a frontline treatment for NDMM patients who are transplant-ineligible or deferred. The CEPHEUS trial highlights DVRd's ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

Now in its ninth year, MM4MM has made tremendous progress and united hundreds of patients, caregivers, and supporters to raise funds that go directly to advancing our mission of accelerating a cure ...

Tamara Mobley's persistent back pain led to a multiple myeloma diagnosis after initial dismissive medical consultations. Her ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...